Neoantigen Cancer Vaccine Market Analysis, Size, Report to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Neoantigen Cancer Vaccine Market Size Analysis

Global Neoantigen Cancer Vaccine Market Introduction
By Product
1. Introduction
  1. Product By Value
2. Personalised neo-antigen vaccine
  1. By Value
3. Off-the-shelf neoantigen vaccine
  1. By Value
By Neoantigen Type
1. Introduction
  1. Neoantigen Type By Value
2. Synthetic Long Peptide
  1. By Value
3. Nucleic acid
  1. By Value
4. Dendritic cell
  1. By Value
5. Tumour cell
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Intramuscular
  1. By Value
4. Transdermal
  1. By Value
5. Others
  1. By Value
By Cell
1. Introduction
  1. Cell By Value
2. Autologous
  1. By Value
3. Allogenic
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. RNA Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. HLA Typing
  1. By Value
By Delivery Mechanism
1. Introduction
  1. Delivery Mechanism By Value
2. Liposomes
  1. By Value
3. Virosomes
  1. By Value
4. Gene gun
  1. By Value
5. Electroporation
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Lung
  1. By Value
3. Melanoma
  1. By Value
4. Gastrointestinal
  1. By Value
5. Brain cancer
  1. By Value
6. Others
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Personalised neo-antigen vaccine
  1. By Value
3. Off-the-shelf neoantigen vaccine
  1. By Value
By Neoantigen Type
1. Introduction
  1. Neoantigen Type By Value
2. Synthetic Long Peptide
  1. By Value
3. Nucleic acid
  1. By Value
4. Dendritic cell
  1. By Value
5. Tumour cell
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Intramuscular
  1. By Value
4. Transdermal
  1. By Value
5. Others
  1. By Value
By Cell
1. Introduction
  1. Cell By Value
2. Autologous
  1. By Value
3. Allogenic
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. RNA Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. HLA Typing
  1. By Value
By Delivery Mechanism
1. Introduction
  1. Delivery Mechanism By Value
2. Liposomes
  1. By Value
3. Virosomes
  1. By Value
4. Gene gun
  1. By Value
5. Electroporation
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Lung
  1. By Value
3. Melanoma
  1. By Value
4. Gastrointestinal
  1. By Value
5. Brain cancer
  1. By Value
6. Others
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. Personalised neo-antigen vaccine
    1. By Value
  3. Off-the-shelf neoantigen vaccine
    1. By Value
2. By Neoantigen Type
  1. Introduction
    1. Neoantigen Type By Value
  2. Synthetic Long Peptide
    1. By Value
  3. Nucleic acid
    1. By Value
  4. Dendritic cell
    1. By Value
  5. Tumour cell
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Intramuscular
    1. By Value
  4. Transdermal
    1. By Value
  5. Others
    1. By Value
4. By Cell
  1. Introduction
    1. Cell By Value
  2. Autologous
    1. By Value
  3. Allogenic
    1. By Value
5. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. HLA Typing
    1. By Value
6. By Delivery Mechanism
  1. Introduction
    1. Delivery Mechanism By Value
  2. Liposomes
    1. By Value
  3. Virosomes
    1. By Value
  4. Gene gun
    1. By Value
  5. Electroporation
    1. By Value
  6. Others
    1. By Value
7. By Application
  1. Introduction
    1. Application By Value
  2. Lung
    1. By Value
  3. Melanoma
    1. By Value
  4. Gastrointestinal
    1. By Value
  5. Brain cancer
    1. By Value
  6. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Personalised neo-antigen vaccine
  1. By Value
3. Off-the-shelf neoantigen vaccine
  1. By Value
By Neoantigen Type
1. Introduction
  1. Neoantigen Type By Value
2. Synthetic Long Peptide
  1. By Value
3. Nucleic acid
  1. By Value
4. Dendritic cell
  1. By Value
5. Tumour cell
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Intramuscular
  1. By Value
4. Transdermal
  1. By Value
5. Others
  1. By Value
By Cell
1. Introduction
  1. Cell By Value
2. Autologous
  1. By Value
3. Allogenic
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. RNA Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. HLA Typing
  1. By Value
By Delivery Mechanism
1. Introduction
  1. Delivery Mechanism By Value
2. Liposomes
  1. By Value
3. Virosomes
  1. By Value
4. Gene gun
  1. By Value
5. Electroporation
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Lung
  1. By Value
3. Melanoma
  1. By Value
4. Gastrointestinal
  1. By Value
5. Brain cancer
  1. By Value
6. Others
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. Personalised neo-antigen vaccine
    1. By Value
  3. Off-the-shelf neoantigen vaccine
    1. By Value
2. By Neoantigen Type
  1. Introduction
    1. Neoantigen Type By Value
  2. Synthetic Long Peptide
    1. By Value
  3. Nucleic acid
    1. By Value
  4. Dendritic cell
    1. By Value
  5. Tumour cell
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Intramuscular
    1. By Value
  4. Transdermal
    1. By Value
  5. Others
    1. By Value
4. By Cell
  1. Introduction
    1. Cell By Value
  2. Autologous
    1. By Value
  3. Allogenic
    1. By Value
5. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. HLA Typing
    1. By Value
6. By Delivery Mechanism
  1. Introduction
    1. Delivery Mechanism By Value
  2. Liposomes
    1. By Value
  3. Virosomes
    1. By Value
  4. Gene gun
    1. By Value
  5. Electroporation
    1. By Value
  6. Others
    1. By Value
7. By Application
  1. Introduction
    1. Application By Value
  2. Lung
    1. By Value
  3. Melanoma
    1. By Value
  4. Gastrointestinal
    1. By Value
  5. Brain cancer
    1. By Value
  6. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Personalised neo-antigen vaccine
  1. By Value
3. Off-the-shelf neoantigen vaccine
  1. By Value
By Neoantigen Type
1. Introduction
  1. Neoantigen Type By Value
2. Synthetic Long Peptide
  1. By Value
3. Nucleic acid
  1. By Value
4. Dendritic cell
  1. By Value
5. Tumour cell
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Intramuscular
  1. By Value
4. Transdermal
  1. By Value
5. Others
  1. By Value
By Cell
1. Introduction
  1. Cell By Value
2. Autologous
  1. By Value
3. Allogenic
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. RNA Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. HLA Typing
  1. By Value
By Delivery Mechanism
1. Introduction
  1. Delivery Mechanism By Value
2. Liposomes
  1. By Value
3. Virosomes
  1. By Value
4. Gene gun
  1. By Value
5. Electroporation
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Lung
  1. By Value
3. Melanoma
  1. By Value
4. Gastrointestinal
  1. By Value
5. Brain cancer
  1. By Value
6. Others
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. Personalised neo-antigen vaccine
    1. By Value
  3. Off-the-shelf neoantigen vaccine
    1. By Value
2. By Neoantigen Type
  1. Introduction
    1. Neoantigen Type By Value
  2. Synthetic Long Peptide
    1. By Value
  3. Nucleic acid
    1. By Value
  4. Dendritic cell
    1. By Value
  5. Tumour cell
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Intramuscular
    1. By Value
  4. Transdermal
    1. By Value
  5. Others
    1. By Value
4. By Cell
  1. Introduction
    1. Cell By Value
  2. Autologous
    1. By Value
  3. Allogenic
    1. By Value
5. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. HLA Typing
    1. By Value
6. By Delivery Mechanism
  1. Introduction
    1. Delivery Mechanism By Value
  2. Liposomes
    1. By Value
  3. Virosomes
    1. By Value
  4. Gene gun
    1. By Value
  5. Electroporation
    1. By Value
  6. Others
    1. By Value
7. By Application
  1. Introduction
    1. Application By Value
  2. Lung
    1. By Value
  3. Melanoma
    1. By Value
  4. Gastrointestinal
    1. By Value
  5. Brain cancer
    1. By Value
  6. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Personalised neo-antigen vaccine
  1. By Value
3. Off-the-shelf neoantigen vaccine
  1. By Value
By Neoantigen Type
1. Introduction
  1. Neoantigen Type By Value
2. Synthetic Long Peptide
  1. By Value
3. Nucleic acid
  1. By Value
4. Dendritic cell
  1. By Value
5. Tumour cell
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Intramuscular
  1. By Value
4. Transdermal
  1. By Value
5. Others
  1. By Value
By Cell
1. Introduction
  1. Cell By Value
2. Autologous
  1. By Value
3. Allogenic
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. RNA Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. HLA Typing
  1. By Value
By Delivery Mechanism
1. Introduction
  1. Delivery Mechanism By Value
2. Liposomes
  1. By Value
3. Virosomes
  1. By Value
4. Gene gun
  1. By Value
5. Electroporation
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Lung
  1. By Value
3. Melanoma
  1. By Value
4. Gastrointestinal
  1. By Value
5. Brain cancer
  1. By Value
6. Others
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. Personalised neo-antigen vaccine
    1. By Value
  3. Off-the-shelf neoantigen vaccine
    1. By Value
2. By Neoantigen Type
  1. Introduction
    1. Neoantigen Type By Value
  2. Synthetic Long Peptide
    1. By Value
  3. Nucleic acid
    1. By Value
  4. Dendritic cell
    1. By Value
  5. Tumour cell
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Intramuscular
    1. By Value
  4. Transdermal
    1. By Value
  5. Others
    1. By Value
4. By Cell
  1. Introduction
    1. Cell By Value
  2. Autologous
    1. By Value
  3. Allogenic
    1. By Value
5. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. HLA Typing
    1. By Value
6. By Delivery Mechanism
  1. Introduction
    1. Delivery Mechanism By Value
  2. Liposomes
    1. By Value
  3. Virosomes
    1. By Value
  4. Gene gun
    1. By Value
  5. Electroporation
    1. By Value
  6. Others
    1. By Value
7. By Application
  1. Introduction
    1. Application By Value
  2. Lung
    1. By Value
  3. Melanoma
    1. By Value
  4. Gastrointestinal
    1. By Value
  5. Brain cancer
    1. By Value
  6. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Personalised neo-antigen vaccine
  1. By Value
3. Off-the-shelf neoantigen vaccine
  1. By Value
By Neoantigen Type
1. Introduction
  1. Neoantigen Type By Value
2. Synthetic Long Peptide
  1. By Value
3. Nucleic acid
  1. By Value
4. Dendritic cell
  1. By Value
5. Tumour cell
  1. By Value
By Route of Administration
1. Introduction
  1. Route of Administration By Value
2. Intravenous
  1. By Value
3. Intramuscular
  1. By Value
4. Transdermal
  1. By Value
5. Others
  1. By Value
By Cell
1. Introduction
  1. Cell By Value
2. Autologous
  1. By Value
3. Allogenic
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. RNA Sequencing
  1. By Value
3. Whole Genome Sequencing
  1. By Value
4. HLA Typing
  1. By Value
By Delivery Mechanism
1. Introduction
  1. Delivery Mechanism By Value
2. Liposomes
  1. By Value
3. Virosomes
  1. By Value
4. Gene gun
  1. By Value
5. Electroporation
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Lung
  1. By Value
3. Melanoma
  1. By Value
4. Gastrointestinal
  1. By Value
5. Brain cancer
  1. By Value
6. Others
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. Personalised neo-antigen vaccine
    1. By Value
  3. Off-the-shelf neoantigen vaccine
    1. By Value
2. By Neoantigen Type
  1. Introduction
    1. Neoantigen Type By Value
  2. Synthetic Long Peptide
    1. By Value
  3. Nucleic acid
    1. By Value
  4. Dendritic cell
    1. By Value
  5. Tumour cell
    1. By Value
3. By Route of Administration
  1. Introduction
    1. Route of Administration By Value
  2. Intravenous
    1. By Value
  3. Intramuscular
    1. By Value
  4. Transdermal
    1. By Value
  5. Others
    1. By Value
4. By Cell
  1. Introduction
    1. Cell By Value
  2. Autologous
    1. By Value
  3. Allogenic
    1. By Value
5. By Technology
  1. Introduction
    1. Technology By Value
  2. RNA Sequencing
    1. By Value
  3. Whole Genome Sequencing
    1. By Value
  4. HLA Typing
    1. By Value
6. By Delivery Mechanism
  1. Introduction
    1. Delivery Mechanism By Value
  2. Liposomes
    1. By Value
  3. Virosomes
    1. By Value
  4. Gene gun
    1. By Value
  5. Electroporation
    1. By Value
  6. Others
    1. By Value
7. By Application
  1. Introduction
    1. Application By Value
  2. Lung
    1. By Value
  3. Melanoma
    1. By Value
  4. Gastrointestinal
    1. By Value
  5. Brain cancer
    1. By Value
  6. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Neoantigen Cancer Vaccine Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

OSE Immunotherapeutics SA
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Gritstone bio Inc.
BioNTech SE
Hoffmann-La Roche Ltd.
Pfizer Inc.
Merck & Co. Inc.
Moderna Inc.
Avidea Technologies Inc.
Eli Lilly and Company
Vaccibody AS
Agenus Inc.
Novogene Co. Ltd.
ZIOPHARM Oncology Inc.
ISA Pharmaceuticals B.V.
BrightPath Biotherapeutics Co. Ltd.
Vaximm AG
Medigene AG
Genocea Biosciences Inc.
Advaxis Inc.
Nouscom AG

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment